Thread by @drpatrickholmes

AMPLITUDE-O Trial
1/5
Cardiovascular outcome trial for Efpeglenatide an investigational once weekly Exendin-4 based GLP-1ra.

What are the unanswered questions
Do Exendin-based GLP-1a ⤵️ MACE❓
Do GLP-1ra ⤵️ MACE in people taking SGLT2i❓
Does GLP-1ra ⤵️ renal decline❓

#ADA2021

2/5
Main results

Efpeglenatide
⤵️3-point MACE by 27%
⤵️expanded MACE by 21%
⤵️Renal composite by 32%
⤵️MACE or non-CV death by 27%

Best data yet to suggest adding GLP-1ra to SGLT2i ⤵️MACE

@DLBHATTMD

3/5
Renal outcomes

Efpeglenatide
⤵️Renal composite
⤵️Albuminuria
⤵️eGFR slope❗️

4/5
How do these results impact on an updated GLP-1ra CVOT meta-analysis?

GLP-1ra
⤵️3-point MACE by 14%
⤵️CV ☠️ by 13%
⤵️MI by 10%
⤵️Stoke by 17%
⤵️hHF by 11%

5/5

Conclusions

Do Exendin-based GLP-1a ⤵️ MACE?✅
Do GLP-1ra ⤵️ MACE in people taking SGLT2i?✅ (⚠️small numbers though)
Does GLP-1ra ⤵️ renal decline?✅

Full slide set
👇
phri.ca/research/ampli…

Full paper
👇
nejm.org/doi/full/10.10…

Oops. Wong images attached 🤦‍♂️